Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 29 · below the Ichimoku cloud · RSI 33 · MACD below its signal · 6% above its 52-week low
None of the 29 investors followed here reported a position in 2552.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 2552.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 14, 2026 | Chen (Li)Chief Executive Officer | — | 750K | — |
| Dec 28, 2025 | Zhang (Yi)Director (Executive) | — | 1.38M | — |
| Dec 11, 2025 | Chen (Li)Chief Executive Officer | — | 750K | — |
| Nov 18, 2025 | Zhang (Yi)Director (Executive) | — | 2.00M | — |
| Nov 17, 2024 | Chen (Li)Chief Executive Officer | — | 200K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.0 | 2.7 | 10.7 | -1.8 | -21.5 | -19.4 | 9.9 | 0.4 | -0.4 | -10.3 | −31.7% | ||
| 2025 | 5.6 | 25.7 | 27.7 | -9.8 | 24.1 | 3.7 | 17.0 | 3.6 | 25.9 | -18.3 | -4.2 | -9.5 | +112.5% |
| 2024 | -13.2 | -8.2 | -6.4 | 8.2 | -6.3 | 3.4 | -17.5 | -9.4 | 14.8 | 31.1 | -18.5 | 2.1 | −26.9% |
| 2023 | 20.6 | -10.0 | -10.8 | -15.7 | -39.3 | -10.8 | 36.4 | -24.9 | 0.6 | -7.6 | 21.7 | 3.1 | −47.3% |
| 2022 | -1.8 | 2.2 | 1.6 | -18.9 | 24.9 | -4.9 | 3.2 | 3.1 | -7.6 | -42.1 | 60.8 | 9.7 | −1.3% |
| 2021 | -4.3 | -10.8 | -9.9 | 8.5 | 2.5 | -5.5 | -14.3 | 14.7 | 2.0 | -11.7 | -1.2 | -7.3 | −34.5% |
| 2020 | -4.6 | -16.3 | -23.8 | -1.6 | 57.0 | 50.3 | -1.1 | -17.1 | -14.0 | -15.2 | 14.7 | 19.4 | +15.6% |
| 2019 | -1.6 | 8.9 | -13.3 | -8.7 | -0.6 | 0.6 | -0.7 | -2.1 | 2.5 | -1.4 | -25.4 | -2.9 | −39.6% |
| 2018 | -15.8 | 9.2 | 9.2 | +0.4% |
Buy / hold / sell counts
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.
No recent headlines.